Liver cancer

Liver cancer: Humanitas expertise that revolutionized surgery

Liver tumors, albeit arising from diverse origins, are all the result of an uncontrolled growth...

Hepatocarcinoma and cholangiocarcinoma: new treatment for liver tumors

In the past several weeks, Deputy Head of Medical Oncology at Humanitas and Professor of...

Advanced hepatocarcinoma: positive results from the Cabozantinib study, in which Humanitas also...

In Italy only 10% of the diagnoses of liver cancer occur at an early stage...

EASL 2018: medicines for liver cirrhosis and risk of liver cancer, the...

From 11 to 15 April, Paris hosted the annual meeting of the European Association for...

EASL 2018: The Role of the Medical Oncologist in the Multidisciplinary Management...

The annual meeting of the European Association for the Study of the Liver (EASL) took...

Hepatocarcinoma: the results of the Humanitas study published in The Lancet Oncology

"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a...

An Award-Winning Feasibility Study Coordinated by Humanitas, on the Planning of Stereotactic...

“Multicentre Treatment Planning Inter-comparison in a National Context. The Liver Stereotactic Ablative Radiotherapy case”. This...